In a patient with pulmonary embolism and multiple recent falls, does the benefit of continued anticoagulation with apixaban outweigh the bleeding risk?

Anticoagulation with Apixaban in PE Patients with Multiple Falls

In a patient with pulmonary embolism and multiple recent falls, continue anticoagulation with apixaban—the benefit of preventing fatal recurrent PE outweighs the bleeding risk, as falls and advanced age are not contraindications to anticoagulation. 1

Evidence-Based Rationale

The decision to continue anticoagulation must prioritize mortality prevention. A decision analysis specifically examining elderly patients with idiopathic PE and fall risk demonstrated that long-term warfarin increased life expectancy by 0.16 to 0.56 years and event-free life expectancy by 0.32 to 0.51 years, with a 76-93% likelihood of benefit even in patients with fall propensity 1. Advanced age and fall risk were explicitly not contraindications to long-term anticoagulation in patients who tolerated initial therapy without major bleeding 1.

Guideline-Directed Management

Initial Treatment Phase (First 3 Months)

• All PE patients require therapeutic anticoagulation for at least 3 months 2, 3
• Apixaban is preferred as a first-line NOAC for PE treatment 2
• During this acute phase, use full-dose apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) 4

Extended Therapy Decision (After 3 Months)

The critical decision point occurs at 3 months. Assess whether the PE was:

Provoked by major transient risk factor: Discontinue anticoagulation 3

Unprovoked or persistent risk factor: Offer extended-phase anticoagulation indefinitely 3

Optimizing Safety in Fall-Risk Patients

For patients requiring extended therapy with fall risk:

• Switch to reduced-dose apixaban (2.5 mg twice daily) after completing initial treatment 3
• This reduced dose maintains efficacy while lowering bleeding risk 3
• Recent data shows apixaban has lower major bleeding rates than rivaroxaban (3.3 vs 4.4 per 100 patient-years during primary treatment) 5

Critical Safety Monitoring

Reassess at regular intervals:

• Drug tolerance and adherence
• Hepatic and renal function
• Bleeding risk 2
• Annual reevaluation of the decision to continue extended anticoagulation 3

Common Pitfalls to Avoid

Do not automatically discontinue anticoagulation based solely on fall history. The mortality risk from recurrent untreated PE (15-30%) far exceeds the risk of fatal intracranial hemorrhage from falls on anticoagulation (approximately 1-2% annually) 1.

Do not use aspirin as a substitute for anticoagulation in patients who want extended therapy. Aspirin is substantially less effective at preventing recurrent VTE and should only be considered if the patient refuses anticoagulation entirely 3.

Do not continue full-dose anticoagulation indefinitely without considering dose reduction. After initial treatment, reduced-dose DOACs are preferred over full-dose for extended therapy 3.

Contraindications to Consider

Anticoagulation should be reconsidered if:

• Severe renal impairment (apixaban contraindicated) 2
• Active major bleeding occurs during initial therapy
• Patient experiences traumatic intracranial hemorrhage (requires multidisciplinary evaluation and may need temporary IVC filter with staged anticoagulation restart) 6

The evidence strongly supports continuing anticoagulation in fall-risk patients who have tolerated initial therapy, using reduced-dose apixaban for extended prevention. 3, 1